Production (Stage)
Alto Neuroscience, Inc.
ANRO
$3.03
$0.103.41%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -63.18M | -61.43M | -57.45M | -49.81M | -42.44M |
| Total Depreciation and Amortization | 576.00K | 502.00K | 444.00K | 385.00K | 384.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.95M | 9.45M | 8.27M | 6.60M | 5.12M |
| Change in Net Operating Assets | -344.00K | 4.06M | 2.81M | 853.00K | 23.00K |
| Cash from Operations | -53.00M | -47.42M | -45.93M | -41.97M | -36.91M |
| Capital Expenditure | -1.88M | -2.08M | -1.92M | -959.00K | -673.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.88M | -2.08M | -1.92M | -959.00K | -673.00K |
| Total Debt Issued | 20.94M | 1.25M | -- | -- | -- |
| Total Debt Repaid | -10.21M | -- | -- | -- | -- |
| Issuance of Common Stock | 375.00K | 137.77M | 137.75M | 137.79M | 137.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 45.00M | 45.00M | 45.00M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -841.00K | -3.33M | -3.97M | -5.28M | -5.08M |
| Cash from Financing | 10.26M | 135.69M | 178.77M | 177.51M | 177.69M |
| Foreign Exchange rate Adjustments | -28.00K | -11.00K | -13.00K | 12.00K | 6.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -44.64M | 86.18M | 130.91M | 134.59M | 140.12M |